Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Research & Development (2016 - 2025)

Historic Research & Development for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $12.3 million.

  • Ani Pharmaceuticals' Research & Development rose 2148.5% to $12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.0 million, marking a year-over-year increase of 4826.99%. This contributed to the annual value of $44.6 million for FY2024, which is 3002.68% up from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Research & Development stood at $12.3 million, which was up 2148.5% from $16.5 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Research & Development registered a high of $16.6 million during Q4 2024, and its lowest value of $2.5 million during Q3 2021.
  • Moreover, its 5-year median value for Research & Development was $7.4 million (2023), whereas its average is $8.0 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Research & Development plummeted by 5321.56% in 2021 and then soared by 21176.71% in 2022.
  • Ani Pharmaceuticals' Research & Development (Quarter) stood at $3.1 million in 2021, then surged by 66.31% to $5.2 million in 2022, then soared by 88.95% to $9.9 million in 2023, then soared by 68.7% to $16.6 million in 2024, then decreased by 26.08% to $12.3 million in 2025.
  • Its Research & Development stands at $12.3 million for Q3 2025, versus $16.5 million for Q2 2025 and $10.6 million for Q1 2025.